LYL BIOTIC intim

Clinical studies

Patented probiotic strains with clinically proven health-promoting properties.

LYLBIOTIC intim

Proven clinical efficacy

The clinical efficacy of LYLBIOTIC intim has been demonstrated in four double-blind, randomized, placebo-controlled studies

Reduces symptoms of vulvovaginal irritation such as itching and discharge

¹ Russo, R., Edu, A. & De Seta, F. Arch Gynecol Obstet 298, 139–145 (2018).

Effectively increases the number of lactic acid bacteria in the vagina

¹ De Alberti, D., Russo, R., Terruzzi, F. et al. Arch Gynecol Obstet 292, 861–867 (2015).

In women with vaginal candidiasis, it reduces itching and discharge, reduces the risk of repeated infections

¹ Russo R, Superti F, Karadja E, De Seta F. Mycoses. 2019; 62: 328–335.

In women with bacterial vaginosis, it reduces itching and discharge, reduces the risk of repeated infections

¹ Russo R, Karadja E, De Seta F. Benef Microbes. 2019 Feb 8;10(1):19-26.

A review of double-blind, randomized, placebo-controlled trials

Study aim: to evaluate the changes in Nugent score in women with intermediate vaginal microbiota treated with oral Lactobacillus acidophilus La-14® and Lactobacillus rhamnosus HN001™ mixture, in combination with bovine lactoferrin RCX™ (Respecta®) or placebo, for 15 days.
La-14® and HN001™ (Probiotic Combo) helped restore healthy vaginal microbiota and alleviated vaginal symptoms in women with average vaginal microbiota scores Study Method: 40 women were treated for 15 days with La-14® and HN001™ 5 billion CFU/day with 50 mg lactoferrin (Respecta®) (probiotic combination)
Study aim: to assess the efficacy of L. acidophilus La-14®, L. rhamnosus HN001™, and lactoferrin on symptoms and recurrence of vulvovaginal candidiasis (VVC) as adjuvant therapy to topical clotrimazole.
La-14® and HN001™ were associated with a significant overall vulvovaginal candidiasis (VVC) cure rate and a reduced VVC recurrence rate 48 women with symptomatic acute episodes of VVC and a documented history of recurrence were treated with topical clotrimazole for seven days and coadministered oral La-14® and HN001™ with lactoferrin (50 mg)
Study aim: to assess the efficacy of Lactobacillus acidophilus La-14® and Lactobacillus rhamnosus HN001™, in combination with lactoferrin as adjuvant therapy to metronidazole in women with recurrent bacterial vaginosis (BV).
La-14® and HN001™ were associated with significant improvement in recurrent BV symptoms, improvement in overall cure rate and reduction in BV recurrence rates Study Method: 48 women with symptomatic BV infections were treated with metronidazole (500 mg twice daily) for 7 days and co-administered oral La-14® and HN001™ with lactoferrin (50 mg)
Study aim: to determine if Lactobacillus acidophilus La-14® and Lactobacillus rhamnosus HN001™ could be detected in the vaginas of healthy women once consumed. A double-blind, randomized, placebo-controlled pilot study.
La-14® and HN001™ probiotic combo supplementation increased vaginal recovery of healthy bacteria and increased transient colonization of healthy bacteria 40 healthy women were randomized into two treatment groups: 1) placebo (100 mg maltodextrin); 2) La-14 ® and HN001 ™ 10 billion CFU per day with lactoferrin

The science behind every LYLBIOTIC intim strain

The patented bacterial strains La-14® and HN001™ confer exclusive rights for their inclusion in LYLBIOTIC Intim

4

Clinical Studies

100+

Team of Scientists

12

Billions of Bacteria

1

Product in Europe

Combination of bacterial strains La-14® and HN001™

The composition of LYLBIOTIC intim consists of a combination of unique, patented probiotic strains Lactobacillus acidophilus La-14® and  Lactobacillus rhamnosus HN001™ , which are clinically proven effective for female urogenital health. 

In order for bacterial strains to be registered , 8 important steps must be taken , starting with the laboratory assessment of bacterial viability and ending with a clinical research base on safety and effects.

A bacterial strain refers to a genetically distinct group within the same species of bacteria capable of exhibiting unique characteristics and abilities. Even within the same species, genetic differences can lead to different characteristics, such as persistence, ability to adhere to the intestinal wall, or specific effects on human health.

Brands often refer to proprietary and clinically-studied probiotic strains to emphasize their products’ unique, scientifically proven health benefits , underscoring the importance of selecting specific strains for targeted health outcomes.

In the field of probiotics, a patent usually covers specific strains that a company has identified and studied to demonstrate their unique health benefits.

Such studies may include clinical trials to evaluate the effects of probiotics on human health, such as improving digestion, improving the immune system, or protecting against certain diseases.

Patenting a probiotic strain gives a company the exclusive right to manufacture and sell it as an ingredient in its products, indicating that the strain has been thoroughly researched and has proven health-promoting properties.

Clinically studied probiotic strains are critical because they provide scientific evidence of safety and efficacy, helping consumers make informed decisions about which probiotic products might be best for their health needs.

The patented strains Lacidophilus (La-14™) and L. rhamnosus (HN001™) included in LYLBIOTIC intim are currently the only strains with which quality studies have been conducted and which have good results in the treatment of bacterial vaginosis.

Clinical effectiveness of LYLBIOTIC:

1)  helps effectively balance the vaginal pH level and promote a healthy vaginal microbiota. [ 1 ]

2) for women with symptoms of vaginal irritation help effectively balance the pH level and promote a healthy vaginal microbiota by promoting bacterial balance. [ 2 ]

3) for women with bacterial vaginosis (BV) help to maintain a healthy vaginal microbiota, thereby promoting bacterial balance and supporting overall vaginal health. BV is considered the most common vaginal infection in women of reproductive age. [ 3 ]

4) for women with vaginal fungal infection – candidiasis helps to maintain a healthy vaginal microbiota, thereby contributing to the balance of bacteria and supporting general vaginal health. Candidiasis is considered the second most common vaginal infection after BV. [ 4 ]

Indications for use of LYLBIOTIC intim:

a) p rophylactic;

b) prophylactically using broad-spectrum antibiotics against any infection;

c) after bacterial vaginosis therapy or during therapy;

d) after antimycotic – vaginal inflammation caused by fungi during therapy or therapy;

e) for recurrent (repeated) urinary tract infections.

The daily dose of LYLBIOTIC intim is only one capsule , which contains 12 billion bacteria.

"Orally taken intimate probiotics are necessary not only for preventive purposes, they are also one of the cornerstones of therapy in the treatment of various diseases associated with changes in the vaginal microflora"

Karlina Elksne
Gynecologist